Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability
journal contributionposted on 08.04.2020, 16:46 by Gergana Popova, Marcus J. G. W. Ladds, Lars Johansson, Aljona Saleh, Johanna Larsson, Lars Sandberg, Sara Häggblad Sahlberg, Weixing Qian, Hjalmar Gullberg, Neeraj Garg, Anna-Lena Gustavsson, Martin Haraldsson, David Lane, Ulrika Yngve, Sonia Lain
Human dihydroorotate dehydrogenase (DHODH), an enzyme in the de novo pyrimidine synthesis pathway, is a target for the treatment of rheumatoid arthritis and multiple sclerosis and is re-emerging as an attractive target for cancer therapy. Here we describe the optimization of recently identified tetrahydroindazoles (HZ) as DHODH inhibitors. Several of the HZ analogues synthesized in this study are highly potent inhibitors of DHODH in an enzymatic assay, while also inhibiting cancer cell growth and viability and activating p53-dependent transcription factor activity in a reporter cell assay. Furthermore, we demonstrate the specificity of the compounds toward the de novo pyrimidine synthesis pathway through supplementation with an excess of uridine. We also show that induction of the DNA damage marker γ-H2AX after DHODH inhibition is preventable by cotreatment with the pan-caspase inhibitor Z-VAD-FMK. Additional solubility and in vitro metabolic stability profiling revealed compound 51 as a favorable candidate for preclinical efficacy studies.
Read the peer-reviewed publication
cancer cell growthpan-caspase inhibitor Z-VAD-FMKpyrimidine synthesis pathwaycompound 51DNA damage marker γ- H 2AXDHODH inhibitorsreporter cell assayHuman Dihydroorotate DehydrogenaseAdditional solubilityHZ analoguesefficacy studiesVitro Metabolic Stability Human dihydroorotate dehydrogenasep 53-dependent transcription factor activityDHODH inhibitioncancer therapy